Inmune Bio Inc (INMB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -40,669 | -34,197 | -9,739 | -42,082 | -32,864 |
| Depreciation Amortization | 28 | N/A | N/A | 79 | 73 |
| Other Working Capital | -1,479 | -126 | 839 | 1,037 | 4,595 |
| Other Operating Activity | 22,482 | 20,124 | 2,076 | 7,605 | 5,848 |
| Operating Cash Flow | $-19,638 | $-14,199 | $-6,824 | $-33,361 | $-22,348 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -899 | -706 | N/A | N/A | N/A |
| Investing Cash Flow | $-899 | $-706 | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | N/A | -10,000 | -7,500 |
| Common Stock Issued | 27,545 | 27,545 | 5,274 | 28,211 | 27,789 |
| Financing Cash Flow | $27,545 | $27,545 | $5,274 | $18,211 | $20,289 |
| Exchange Rate Effect | -196 | -188 | -35 | 224 | -237 |
| Beginning Cash Position | 20,922 | 20,922 | 20,922 | 35,848 | 35,848 |
| End Cash Position | 27,734 | 33,374 | 19,337 | 20,922 | 33,552 |
| Net Cash Flow | $6,812 | $12,452 | $-1,585 | $-14,926 | $-2,296 |
| Free Cash Flow | |||||
| Operating Cash Flow | -19,638 | -14,199 | -6,824 | -33,361 | -22,348 |
| Capital Expenditure | -899 | -706 | N/A | N/A | N/A |
| Free Cash Flow | -20,537 | -14,905 | -6,824 | -33,361 | -22,348 |